Quest Diagnostics IncorporatedNYSE: DGX
Health Care · Health Care Services
$192.98
-0.63%
Vol: 427K
Research Digest
Friday, May 1, 2026
Quest Diagnostics Q1 beats with 13.1% adjusted EPS growth and raised full-year guidance
Quest Diagnostics reported strong Q1 2026 results with net revenues of $2.90 billion (+9.2% YoY) and adjusted diluted EPS of $2.50 (+13.1%). Company raised full-year 2026 guidance with adjusted EPS now $10.63-$10.83. Increased dividend 7.5% to $0.86 per quarter, marking 15 consecutive years of increases. Launched AI companion tool with Google Cloud partnership. Priced $500 million senior notes offering.
Previous Market Intelligence
13 daysApr 30Quest Diagnostics reported Q1 2026 revenue of $2.9B (up 9.2%) and adjusted EPS of $2.50 (up 5.49%), and raised full-year guidance to $10.82 EPS with $11.76B revenue expected.Positive▶
Quest Diagnostics exceeded expectations in Q1 2026 with $2.9B revenue (up 9.2% YoY) and adjusted EPS of $2.50. The company raised full-year guidance to $10.82 EPS and $11.76B revenue reflecting continued diagnostic demand momentum. Quest priced $500M of 5.00% senior notes due 2036 with net proceeds expected May 6 to refinance maturing debt. Strategic developments include research collaboration with City of Hope on cancer monitoring and launch of AI Companion tool for patient lab report understanding with 350K+ engagements since Q1. Baird raised PT to $229 from $224; BofA to $245 from $225.
Apr 29Quest Diagnostics beats Q1 2026 earnings and raises full-year guidance; increases dividend 7.5% and prices $500M senior notesPositive▶
Quest Diagnostics reported strong Q1 2026 performance, exceeding expectations with net revenues of $2.90B (+9.2% YoY) and reported diluted EPS of $2.24 (+15.5%). Adjusted diluted EPS rose to $2.50, up 13.1%, beating consensus of $2.37. Company raised FY26 guidance to net revenues of $11.78–$11.90B and adjusted diluted EPS at $10.63–$10.83. Increased quarterly dividend 7.5% to $0.86, marking 15 consecutive years of increases, and announced $1B increase in share repurchase authorization. April 27, company priced $500M of 5.000% senior notes due 2036. Also launched Quest AI Companion powered by Google Gemini for lab result analysis. Average 12-month price target is $222.56 with Buy consensus (9 analysts).
Apr 16Quest Diagnostics beat Q4 2025 revenue forecast $2.81B, up 7%; raised dividend 7.5% to $0.86 quarterly.Positive▶
Quest Diagnostics reported Q4 2025 revenue of $2.81 billion, up 7% year-over-year from $2.62 billion, beating consensus estimate of $2.76 billion. Requisition volumes rose 9% in quarter, organic requisition volume growth 8% year-over-year. Reported diluted EPS of $2.18, up 11.8% from 2024, and adjusted EPS of $2.42, up 8.5%. Raised dividend 7.5% to $0.86 per share, marking 15 consecutive years of increases. Announced $1 billion share repurchase authorization increase. Timothy Wentworth elected to Board in March 2026. Stock at $195.26 with market cap 21.46B. Analyst consensus Buy with target $208.62.
Apr 15Quest Diagnostics raises dividend 7.5% to $0.86 per share; Q1 2026 earnings due April 21.Positive▶
Quest Diagnostics Board authorized a 7.5% quarterly dividend increase to $0.86 per share, marking 15 consecutive years of increases. Also announced a $1 billion share repurchase authorization increase. Q1 2026 results due April 21. FY 2026 guidance: revenues $11.70-$11.82B, adjusted diluted EPS $10.50-$10.70. Analyst consensus is Buy with $208.62 price target.
Apr 14Quest Diagnostics Q1 2026 earnings due April 21; dividend increased 7.5% to $0.86 and $1B share repurchase expansion.Positive▶
Quest Diagnostics Q1 2026 results April 21 before market open. Increased quarterly dividend 7.5% to $0.86 (15 consecutive years of increases). Announced $1B share repurchase expansion. Q4 2025 EPS $2.42 beating $2.35 estimates. New executive appointments including SVP Chief Strategy and M&A.
Apr 13Quest Diagnostics reports FY25 revenue of $11.04B; Q1 2026 earnings due April 21; Flow Cytometry MRD blood test launched.Positive▶
Quest Diagnostics reported FY 2025 revenue of $11.04B with adjusted EPS of $9.85. 2026 guidance: $11.70-$11.82B revenues. Q1 2026 earnings April 21. Launched Flow Cytometry MRD blood test for Myeloma. Named to Fortune 2026 Most Admired Companies. Dividend increased 7.5% to $0.86. Consensus Buy with PT $208.62.
Apr 10Quest Diagnostics increases dividend 7.5%; launches AI CompanionPositive▶
FY2025 revenues $11.04B (+11.8%), adjusted EPS $9.85 (+9.4%). Dividend increased 7.5%. Launched Quest AI Companion with Google Gemini.
Apr 9Quest Diagnostics Q4 2025 shows strong growth with AI innovations and 2026 guidancePositive▶
Quest reported Q4 2025 net revenues of $2.81B (+7.1% YoY) and full-year 2025 revenues of $11.04B (+11.8%). The company raised quarterly dividend 7.5% to $0.86 per share and provided 2026 guidance of $11.70-11.82B revenues and adjusted EPS of $10.50-10.70. Quest launched Quest AI Companion powered by Google Gemini and Quest Flow Cytometry MRD for Myeloma in February 2026. Q1 2026 earnings scheduled for April 21. Fortune named Quest to 2026 World's Most Admired Companies for 12th consecutive year.
Apr 8Quest Diagnostics increases dividend 7.5% to $0.86; 15 consecutive years of increases.Positive▶
DGX Q4 revenue +7% YoY to $2.81B. Forecasted 2026 above estimates. Increased dividend 7.5% to $0.86. CEO highlighted Alzheimer's blood testing. Q1 results April 21.
Apr 7Quest Diagnostics launches Quest AI Companion; Board elects Timothy WentworthPositive▶
Quest Diagnostics launched Quest AI Companion (March 2) - AI chat analyzing 5 years of lab data. Timothy Wentworth (former Walgreens/Evernorth CEO) elected to board (March 12). Q4 2025 revenues up 7.1% to $2.81B; FY2025 revenues up 11.8% to $11.04B. 2026 guidance: $11.70-11.82B revenue, $10.50-10.70 EPS. 7.5% dividend increase to $0.86/share.
Apr 6Quest Diagnostics raises dividend 7.5% and expands diagnostic test portfolio with novel MRD blood test.Positive▶
Quest Diagnostics reported strong Q4 2025 results with revenues of $2.81 billion up 7.1% and diluted EPS of $2.18 up 11.8% year-over-year. The company increased its quarterly dividend by 7.5% to $0.86 per share, marking 15 consecutive years of dividend increases. Quest launched a novel flow cytometry MRD blood test for myeloma with ultrasensitive detection capabilities. Timothy Wentworth was elected to the Board of Directors in March 2026. Mizuho Securities issued a Buy rating.
Apr 3Quest Diagnostics increases dividend 7.5%; Q1 2026 earnings expected with strong EPS growth guidance.Positive▶
Quest Diagnostics increased its quarterly dividend by 7.5% to $0.86 per share, marking 15 consecutive years of increases. Announced a $1 billion increase in share repurchase authorization. Q4 2025 revenue of $2.81B (up 7.1%) with diluted EPS of $2.18 (up 11.8%). Consensus target $218.50.
Apr 2Quest Diagnostics increases quarterly dividend 7.5% to $0.86 and announces $1B share repurchase expansion amid 15-year dividend increase streak.Positive▶
Quest Diagnostics announced a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80, effective with the dividend payable on April 20, 2026. This marks the 15th consecutive year of dividend increases, raising the annual cash dividend to $3.44 per share. The company also announced a $1 billion increase in share repurchase authorization. Q4 2025 net revenues reached $2.81 billion (up 7.1%) with full-year 2025 revenues of $11.04 billion (up 11.8%). The company provided 2026 guidance of $11.70-$11.82 billion in revenues and adjusted EPS of $10.50-$10.70. Quest Diagnostics was named to Fortune's 2026 World's Most Admired Companies list. Analysts maintain a consensus "Buy" rating with a $218.50 average price target.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.